Strategy for the Prediction and Selection of Drug Substance Salt Forms - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Strategy for the Prediction and Selection of Drug Substance Salt Forms
Through consideration of the ionic equilibria of acids and bases, one may readily calculate the formation constant of a salt species solely on the basis of knowledge of the pKA value of the acid and the pKB value of the base.


Pharmaceutical Technology



Figure 1: Degree of salt formation calculated for the reaction of ibuprofen with basic substances of varying pK values, where it may be noted that the 99% formation criterion interacts with the curve at a pK A value of 8.41.
To further illustrate the strategy that would be used to select the range of salt-forming species for a particular drug substance, consider a hypothetical selection process for ibuprofen. The pK A of this acidic compound is 4.41 (16), and equations 25 and 26 can be used to calculate the degree of salt formation as a function of the pK A value of potential basic salt-formers. These results are plotted in Figure 1, and if one accepts the definition of an appropriate salt as one whose degree of formation equals 99% or higher, then one would only form ibuprofen salts with bases whose pK A values exceed 8.41. The formation of sodium or potassium salts (for which pK A is approximately 14) is obvious, as would be the formation of salts with arginine (pK A = 9.59), lysine (pK A = 9.48), ethanolamine (pK A = 9.16), diethanolamine (pK A = 8.71), and erbumine (pK A = 10.68).

The preparation of these salts could be affected by the simple mixing of equimolar amounts of ibuprofen and the pharmaceutically acceptable bases deduced to have appropriate pK A values. These salts would be evaluated on the basis of the degree of acceptability associated with their solubility, hygroscopicity, or other physical properties. For example, the tiered acceptability criteria outlined in Morris et al. could be used to design the program of salt form evaluation (8).

Conclusions

The identification of a salt form of an active pharmaceutical ingredient becomes essential if the characteristics of the free acid or free base are not found to be acceptable. Selection of an appropriate salt form of a chemical entity provides one with the possibility to selectively modify the aqueous solubility, dissolution rate, solution pH, crystal form, hygroscopicity, chemical stability, melting point, or mechanical properties of a drug substance. The identification of suitable counterions to be used in the formation of acceptable salt forms does not have to be conducted following trial-and-error methodologies, but instead appropriate salt-forming candidates can be readily identified through knowledge of the magnitude of the ionization constants of the acids and bases involved.

An equation has been developed based on the ionic equilibria of acids and bases that permits one to calculate the formation constant of a salt species solely on the basis of knowledge of the pK A value of the acid and the pK B value of the base. The initial stages of a salt-selection process for a particular drug substance would begin with knowledge of its ionization constants and culminate with the calculation of the range of ionization constants of salt-forming agents that would ensure the formation of salts in high degrees of efficiency. The salt forms identified in this manner would be predicted to be stable with respect to disproportionation.

Harry G. Brittain, PhD, is the director of the Center for Pharmaceutical Physics and a member of Pharmaceutical Technology's editorial advisory board, 10 Charles Rd., Milford, NJ 08848, tel. 908.996.3509, fax 908.996.3560,

References

1. S.M. Berge, L.D. Bighley, and D.C. Monkhouse, "Pharmaceutical Salts," J. Pharm. Sci. 66 (1), 1–19 (1977).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here